NEW YORK, April 21 - Structural GenomiX (SGX) said today that it has entered a research collaboration with Eli Lilly based on its 3D structure determination technology.
SGX will apply its technology to several Lilly drug targets to determine their three-dimensional structures and generate data on compounds that bind to the drug targets. SGX will also install its technology for Lilly in a high-throughput structural biology facility the company is planning for protein engineering, crystallization, and structure determination.
"The financial benefits to SGX of both the research collaboration and the technology transfer arrangements are substantial," said SGX CEO Tim Harris in a statement. "Further, Lilly is committed to implementing SGX's gene-to-structure platform in their drug discovery programs. This is not a proof-of-principle deal."
Lilly has committed to supporting the research collaboration for at least two years, with an option to extend to a third year.